Company Abbreviation:Lianchuang Biological Medicine,Stock code:800055

News | inflammatory spinal disease treatment, Abbvie JAK inhibitor in two phase 3 clinical test the primary end point

On October 7, 2021, AbbVie announced that upadacitinib (Rinvoq), an oral JAK inhibitor, met its primary end point in two phase 3 trials in adult patients with axial spondylitis (axSpA).

Two phase 3 clinical trial results show that when the 14th week, no matter in the radiology axis in patients with spinal arthritis (nr - axSpA), or in the biological treatment of activity in patients with ankylosing spondylitis (AS), compared with placebo, deuba for group, more patients to the international association of spinal arthritis (ASAS) 40 response. Patients experienced statistically significant reductions in symptoms, including back pain and inflammation, as well as improvements in physical function and disease activity. Axial spondyloarthritis is a chronic inflammatory disease that affects the spine, causing back pain, limited mobility, and structural damage.
In patients with active ankylosing spondylitis (AS)
Forty-five percent of patients in the upatinib group met ASAS40 criteria, significantly better than 18 percent in the placebo group.

In addition, upatinib met multiple secondary end points of the trial, as shown in the figure below.
Safety data were consistent with previous studies, and no new risks were identified.

Image source: Reference [1]

In patients with active nonradiographic axial spondyloarthritis
ASAS40 criteria were met in 45% of patients in the upatinib group, significantly higher than in the placebo group (23%).
· In addition, upatinib met multiple secondary end points of the trial, as shown in the figure below.

Image source: Reference [2]
"Ankylosing spondylitis is a debilitating condition that can cause severe pain, stiffness, limited mobility, and lasting structural damage that severely impacts the patient's daily life."    "Similarly, patients with active nonradiological axial spondyloarthritis suffer from chronic inflammatory back pain and limited physical function," said Dr. Michael Severino, Vice Chairman and President of AbbVie. These patients need treatments that help them improve their physical function and quality of life. We are encouraged by the potential for upatinib to meaningfully control the disease and alleviate these symptoms."
Discovered and developed by AbbVie scientists, upatinib is an oral once-daily, selective and reversible JAK inhibitor. In August 2019, it was approved by the US FDA for the treatment of adults with moderate-to-severe active rheumatoid arthritis who have an insufficient response to or intolerance to methotrexate. The JAK family of proteins mediates the signaling of various inflammatory factors. Upatinib has shown positive results in phase 3 clinical trials for a variety of inflammatory diseases, including rheumatoid arthritis, atopic dermatitis, Crohn's disease, and psoriatic arthritis.

[1] AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis. Retrieved October 7, 2021, from hase-3-study-in-ankylosing- spondylitis-3013951010.html [2] AbbVie's upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis. Retrieved October 7, 2021, from phase-3-study-for-non-radiographic-axial-spondyloarthritis-301395109.html

more> Contact Us